

# Biopharmaceutical Company Selects West's NovaPure® 1mL Long Plunger for First Commercial Drug Launch

## Case Study

### The Challenge

A small biopharmaceutical company looking to launch their first drug, reached out to West Pharmaceutical Services, Inc. (West) seeking recommendations for packaging solutions for one of their pre-clinical drugs. With limited resources and little expertise in containment and delivery of injectable medicines, they needed an experienced supplier that fully understood the challenges of delivering a biologic drug to the market.



### The Considerations

The company identified several critical factors for a successful drug launch, including locating high quality packaging with low risk of particulates and finding a dependable partner they could rely on throughout the length of their drug development. Because this was their first drug launch, it was critical to have high quality components to help ensure the lowest level of risk for their drug launch. Equally important was selecting a supplier with superior technical, quality and regulatory capabilities that could support and guide them through the drug development timeline.

### The Solution

The company selected West's NovaPure® 1mL long plunger, its highest quality offering. The low particulate specifications, Quality by Design principles and breakloose extrusion performance were critical aspects of this product, which made it the right choice for their drug product. Throughout their clinical studies, there was regular communication, including cross functional support from West's technical, analytical, quality, product management and regulatory teams. The teams worked together to leverage West's knowledge and experience in containment and delivery of injectable medicines to bring this drug to market. In 2018, the company successfully launched their drug in Europe and Australia, with plans to launch in the United States in Q4 2020. Going forward, the company has decided on a platform approach and selected the NovaPure 1mL long plunger for all seven of their pipeline programs. This decision highlights the outcome of a successful and trusted partnership, where West's support and NovaPure component offering were equally important factors in the company's successful drug launch. The platform approach provides a strong foundation between the two companies to help bring future drug therapies to market.